<html><body><h2>Case: 1287695907559</h2>
72.0 year old Native_American female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Systolic_BP</td><td width="200">134</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">39</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">BUN</td><td width="200">60</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">62</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Creatinine</td><td width="200">4.0</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">105</td><td width="200">2010-8-20</td></tr>
<tr><td width="200">Pulse</td><td width="200">71</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Age</td><td width="200">72</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Hypertension</td><td width="200">Hypertension</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200">Coronary Artery Disease</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200">Hyperlipidemia</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">CKD</td><td width="200">CKD</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200">Myocardial Infarction</td><td width="200">2010-6-18</td></tr>
<tr><td width="200">Race</td><td width="200">Native_American</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">female</td><td width="200"></td></tr>
</table>
<p><b>Medications:</b> simvastatin(20.0) furosemide(40.0) nitrate(0.4) metoprolol_SA(100.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">Renal_insufficiency_w_creat>=2.1</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(4.0/2010-8-20)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(39.0/2010-8-20)]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[HDL_Cholesterol(39.0/2010-8-20)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[presence of CKD (icd9 codes)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[taking furosemide && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">active prescription for furosemide</td>
<td width="200"></td>
<td width="200"> active prescription for furosemide[taking furosemide]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(72.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.0/2010-8-20) && presence of MI]()</td></tr>
<tr><td width="200">MI no HF</td>
<td width="200"></td>
<td width="200"> MI no HF[Absence of HF && Presence of MI]()</td></tr>
<tr><td width="200">Absence of Stage D HF</td>
<td width="200"></td>
<td width="200"> Absence of Stage D HF[NOT refractory end stage HF (Stage D)Stage D HF (refractory end stage HF)]()</td></tr>
<tr><td width="200">High Risk for HF and DM, HTN, or atherosclerotic vascular disease</td>
<td width="200"></td>
<td width="200"> High Risk for HF and DM, HTN, or atherosclerotic vascular disease[Presence of hypertension]()</td></tr>
<tr><td width="200">Most recent K>=5</td>
<td width="200"></td>
<td width="200"> Most recent K>=5[Potassium(5.0/2010-8-20)]()</td></tr>
<tr><td width="200">Renal-Urinary_Diseases</td>
<td width="200">2010-06-18</td>
<td width="200"> CKD()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">2010-06-18</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">2010-06-18</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">2010-06-18</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.0/2010-8-20) && presence of MI]()</td></tr>
<tr><td width="200">Metabolic&Nutritional_Diseases</td>
<td width="200">2010-06-18</td>
<td width="200"> Disorders Lipid Metabolism()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.0/2010-8-20) && presence of MI]()</td></tr>
<tr><td width="200">Age>=65 and creatinine>=2</td>
<td width="200"></td>
<td width="200"> Age>=65 and creatinine>=2[Age(72.0/1970-1-1) && Creatinine(4.0/2010-8-20)]()</td></tr>
<tr><td width="200">Serum creatinine >=2</td>
<td width="200"></td>
<td width="200"> Serum creatinine >=2mg/dl[Creatinine(4.0/2010-8-20)]()</td></tr>
<tr><td width="200">High Risk Group</td>
<td width="200"></td>
<td width="200"> High Risk Group[Presence of hypertension]()</td></tr>
<tr><td width="200">Age>65?</td>
<td width="200"></td>
<td width="200"> Age>65?[Age(72.0/1970-1-1)]()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200"></td>
<td width="200"> Sex()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
</table><p>
<h1 align="center">ATHENA Heart Failure Guideline</h1>
<b>Patient classification:</b> <ul>
<li>ATHENA Heart Failure Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(NOT refractory end stage HF (Stage D)Stage D HF (refractory end stage HF))</i>]
</ul>
<b>Scenario choice:</b> Stage B HF
<p>
<b>Goal:</b> SBP < 140 and DBP < 90(absence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null))
<p>
<b>Goal:</b> LDL< 160 mg/dL(0-1 risk factors)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(105.0/2010-8-20))
<p><b>Messages by Types</b>
<ul>
<li><b>Class III</b>
<ul>
<li>Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
</ul>
<li><b>Class I</b>
<ul>
<li>Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>Stage A messages</b><br>
<ul>
<li><b>behavior control <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Patients at high risk for developing HF should be counseled to
avoid behaviors that may increase the risk of HF (e.g., smoking,
excessive alcohol consumption, and illicit drug use). (Level of
Evidence: C)
<li><b>Periodic evaluation <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Healthcare providers should perform periodic evaluation for signs
and symptoms of HF in patients at high risk for developing HF.
(Level of Evidence: C)
<li><b>not use nutritional supplements <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
Routine use of nutritional supplements solely to prevent the development of structural heart disease should not be recommended for patients at high risk for developing HF. (Level of
Evidence: C)
</ul>
<li><b>Secondary prevention</b><br>
<ul>
<li><b>Stage B HF action <font color=FF0000>preferred</font></b>(strict rule-in condition<i> true</i> evaluate to <b> true</i>)])

Use of nutritional supplements to treat structural heart disease or to prevent the development of symptoms of HF is NOT recommended.
Coronary revascularization should be recommended in appropriate patients without symptoms of HF in accordance with contemporary guidelines (see ACC/AHA/ACP-ASIM Guidelines for the Management of Patients With Chronic Stable Angina).
</ul>
</ul>
<b>Considerations for adding drug: </b><ul>
<li>Ace_Inhibitor(Captopril, Lisinopril)
<ul>
<li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction) </font>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[Presence of hypertension]) 
<li>rec add ace: dose adjustent based on kidney functio(Refer to specific ACE Inhibitor dose adjustments based on kidney function.)
<li>monitoring renal function and K(Need to find content)
<li>preference: preferred
</ul>
<li>Beta blocker stage B post MI(Carvedilol)
<ul>
<li><font color=FF0000>Compelling indications:  MI no HF(MI no HF[Absence of HF && Presence of MI]) </font>
<li>preference: preferred
</ul>
<li>ARB
<ul>
<li>Relative indications:  High Risk for HF and DM, HTN, or atherosclerotic vascular disease(High Risk for HF and DM, HTN, or atherosclerotic vascular disease[Presence of hypertension]) 
<li>preference: preferred
</ul>
<li>digoxin
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>Beta Blocker Stage B no MI
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>NDHP CCB
<ul>
<li>Contraindications:  Myocardial_Infarction(Myocardial_Infarction) 
<li>preference: ruled out
</ul>
</ul>
<h2>ATHENA CKD Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA CKD Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(72.0/1970-1-1) && Absence of end-stage renal disease && Absence of kidney transplant && Presence of hypertension)</i>]
</ul>
<b>Scenario choice:</b> HTN, no DM, no CKD, no abnormal Cr 3 months apart
<p><b>Action Choices</b>
<ul>
<li><b>Need screening?</b><br>
<ul>
</ul>
</ul>
<h2>ATHENA Diabetes Mellitus: Foot Care</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Diabetes Mellitus: Foot Care: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that diabetes_mellitus)</i>]
</ul>
No scenario chosen.
<h2>ATHENA DM: Eye Care</h2>
<b>Patient classification:</b> <ul>
</ul>
<b>Scenario choice:</b> Eye exam over a year ago or no data
<p><b>Action Choices</b>
<ul>
<li><b>Referral for eye exam over a year or no data</b><br>
<ul>
</ul>
</ul>
<h2>ATHENA DM: Glycemic Control</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA DM: Glycemic Control: false[because <i> Eligibility criteria </i> evaluate to <b>false</b><i>(It is not the case that diabetes_mellitus)</i>]
</ul>
No scenario chosen.
<h2>ATHENA Lipid Management Guideline</h2>
<b>Patient classification:</b> <ul>
<li>ATHENA Lipid Management Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(Age(72.0/1970-1-1) && Absence of Pregnancy)</i>]
<li>0-1 Risk Factor: [because <i> Absence of CHD/CHD Equivalent and 0-1 Risk Factors </i> evaluate to <b>true</b><i>(Absence of risk factor && CHD_Or_CHDEquivalent)</i>]
</ul>
<b>Scenario choice:</b> Drug Therapy (1 drug)
<p>
<b>Goal:</b> LDL< 160 mg/dL(0-1 risk factors)
<p><b>Reached goal?</b> achieved(LDL_Cholesterol(105.0/2010-8-20))
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>1-drug therapy choice</b><br>
<ul>
<li><b>Continue current therapies and monitor <font color=FF0000>preferred</font></b>(strict rule-in condition<i> LDL< 160 mg/dL</i> evaluate to <b> true</b> because <i>LDL_Cholesterol(105.0/2010-8-20)</i>)])
<b><font color=red>LDL within goal. Great job.</font>
</ul>
</ul>
<h2>VA/JNC-VII Hypertension Guideline</h2>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: unknown[because <i> Eligibility criteria </i> evaluate to <b>unknown</b><i>(eGFR(no value))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of TOD/CCD)</i>]
</ul>
<b>Scenario choice:</b> on one anti-hypertensive drug
<p>
<b>Goal:</b> SBP < 140 and DBP < 90(absence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.
</ul>
<li><b>Recommendation</b>
<ul>
<li>Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: nitrate, metoprolol_SA, simvastatin, furosemide
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>risk group C message(on med), absence of DM <font color=FF0000>preferred</font></b>(rule in criterion<i> risk group C</i> evaluate to <b> true</b> because <i>risk group C</i>)])
This patient has clinically manifest cardiovascular disease or target organ damage (Risk Group C per JNC6).  The largest benefit of anti-hypertensive therapy is seen in patients with the highest baseline risk of cardiovascular disease, therefore this patient should be considered for prompt pharmacologic therapy, even if the BP is in the high-normal range.  Appropriate lifestyle modification and attention to other reversible cardiovascular risk factors is also strongly recommended.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>Furosemide without CHF or RF <font color=FF0000>preferred</font></b>(rule in criterion<i> On Furosemide with No CHF or RF</i> evaluate to <b> true</b> because <i>taking loop diuretic (furosemide ) && absence of heart failure && absence of renal insufficiency</i>)])
Patient is taking furosemide or a loop diuretic and appears to have neither CHF nor renal insufficiency. Hydrochlorothiazide is generally a more efficacious diuretic in the management of hypertension.
<li><b>On beta blocker hyperlipidemia <font color=FF0000>preferred</font></b>(rule in criterion<i> beta blocker being used</i> evaluate to <b> true</b> because <i>beta blocker being used</i>)])
Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: nitrate, metoprolol_SA, simvastatin, furosemide
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>one-drug-therapy-choices</b><br>
<ul>
<li><b>on one drug, consider substituting drug <font color=FF0000>preferred</font></b>(strict rule-in condition<i> BP controlled and exist non-indicated current drug and compellingly indicated drug</i> evaluate to <b> true</b> because <i>Treatment_Diastolic_BP(62/null) && Treatment_Systolic_BP(134/null) && there exists a compellingly indicated drug that is not already given && there exists a non-betablocker, non-ACE, non-clonidine , non (alpha blocker + BPH)drug to replace</i>)])

Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.
</ul>
<li><b>substitution messages</b><br>
<ul>
<li><b>NO ADE recommended drug SUB <font color=FF0000>preferred</font></b>(rule in criterion<i> there exists recommended drug and none has ADE</i> evaluate to <b> true</b> because <i>No recommended drug has adverse event && recommend delete</i>)])
No adverse reactions are listed for the antihypertensive drug(s) we are recommending.  If the patient has had an adverse reaction, please enter it in a progress note entitled "Adverse Reactions/Allergy".
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul>
<li> Substitution: replace 
<ul>
<li>furosemide(Loop_diuretics)
<ul>
<li>Furosemide without CHF or RF(Patient is taking furosemide and appears to have neither CHF nor renal failure. Hydrochlorothiazide is generally the more efficacious diuretic in the management of hypertension.)
</ul>
 with <li>Alpha Blocker (terazosin)
<ul>
<li>preference: neutral
<li>No comment
</ul>
<li>DHP Calcium Channel Blocker (felodipine, nifedipine SA)
<ul>
<li>Drugs to partner:  Beta-Blockers(metoprolol_SA) 
<li>preference: neutral
</ul>
<li>(non-DHP) Calcium Channel Blocker (diltiazem)
<ul>
<li>Drugs with bad interactions:  Beta-Blockers(metoprolol_SA) 
<li>Relative indications:  CKD by eGFR or ICD9 codes(CKD[presence of CKD (icd9 codes)]) 
<li>preference: ruled out
</ul>
<li>Potassium Sparing Diuretic 
<ul>
<li>Relative contraindications:  Renal_insufficiency_w_creat>=2.1(Renal Insufficiency[Creatinine(4.0/2010-8-20)]) 
<li>preference: neutral
</ul>
<li>ACE Inhibitor (lisinopril)
<ul>
<li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[presence of CKD (icd9 codes)]) </font>
<li>MI (ACE) and JNC7 rec aldosterone antagonists(ACE Inhibitor is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.)
<li>Add ACE/ARB & CKD; alert creatinine rise(A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.)
<li>preference: preferred
</ul>
<li>Thiazide Diuretic (HCTZ)
<ul>
<li>Drugs with bad interactions:  furosemide(furosemide) 
<li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD[presence of CKD (icd9 codes)]) </font>
<li>HCTZ dosing message and CR>2.0(While most patients do not benefit from doses of HCTZ above 25 mg, patients with mild renal insufficiency may have added benefit from higher doses both for hypertension and fluid management.)
<li>preference: preferred
</ul>
</ul>

</ul>
